SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 61.00 millions for the March 2025 quarter. The mentioned figure indicates a decline of about -49.05% as against Rs. 119.73 millions during the year-ago period.The Net Loss for the quarter ended March 2025 is Rs. -82.68 millions as compared to Net Loss of Rs. -58.48 millions of corresponding quarter ended March 2024 Operating profit Margin for the quarter ended March 2025 further decreased to -50.69% as compared to -29.04% of corresponding quarter ended March 2024


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202503 202403 % Var 202503 202403 % Var 202503 202403 % Var
Sales 61.00 119.73 -49.05 433.12 504.22 -14.10 433.12 504.22 -14.10
Other Income 3.38 2.10 60.95 7.09 4.51 57.21 7.09 4.51 57.21
PBIDT -50.69 -29.04 74.55 -143.21 -82.72 73.13 -143.21 -82.72 73.13
Interest 16.15 12.72 26.97 59.14 46.89 26.12 59.14 46.89 26.12
PBDT -66.84 -41.76 60.06 -202.35 -129.61 56.12 -202.35 -129.61 56.12
Depreciation 15.69 16.72 -6.16 66.89 67.66 -1.14 66.89 67.66 -1.14
PBT -82.53 -58.48 41.13 -269.24 -197.27 36.48 -269.24 -197.27 36.48
TAX 0.15 0.00 0.00 0.15 0.00 0.00 0.15 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -82.68 -58.48 41.38 -269.39 -197.27 36.56 -269.39 -197.27 36.56
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -83.10 -24.25 242.61 -33.06 -16.41 101.55 -33.06 -16.41 101.55

Krebs Biochem.&Inds Share Price

60.20 0.20 (0.33%)
11-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1872.40
Dr. Reddys Lab 1279.70
Cipla 1304.70
Zydus Lifesciences 956.65
Lupin 2245.65
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×